Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE)
Background Randomized controlled trials (RCTs) demonstrated the advantages of an aerosol foam formulation of calcipotriol/betamethasone dipropionate (Cal/BD) in patients with psoriasis. In this review, we investigated whether such benefits could also be obtained in real-world clinical practice. Meth...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-11-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2020.1717417 |
| _version_ | 1797683628399919104 |
|---|---|
| author | Sascha Gerdes Manuel Velasco Jashin J. Wu Mario Hubo Karen A. Veverka |
| author_facet | Sascha Gerdes Manuel Velasco Jashin J. Wu Mario Hubo Karen A. Veverka |
| author_sort | Sascha Gerdes |
| collection | DOAJ |
| description | Background Randomized controlled trials (RCTs) demonstrated the advantages of an aerosol foam formulation of calcipotriol/betamethasone dipropionate (Cal/BD) in patients with psoriasis. In this review, we investigated whether such benefits could also be obtained in real-world clinical practice. Methods PubMed was searched for studies reporting real-world data in patients with psoriasis treated with Cal/BD aerosol foam. Results Three large real-world studies with Cal/BD aerosol foam were identified: a prospective non-interventional study from Germany, a medical chart review from the US, and a retrospective non-interventional study from Spain. Some key findings included the following: high levels of adherence to treatment (82–93%); after 4 weeks, about 50% of patients achieved complete/almost complete responses; at final assessment, 85–95% of patients were extremely satisfied/very satisfied/satisfied with Cal/BD aerosol foam; all healthcare providers were satisfied or somewhat satisfied with the efficacy of Cal/BD foam and they reported similar findings for symptom improvements (itch, pain, erythema/redness, flaking, and plaque thickness). Global ratings by investigators/healthcare providers for symptom control, overall efficacy and the emotional status of patients were also very high (75–100%). Conclusion The results from real-world studies undertaken in diverse healthcare systems reinforce the positive findings reported in RCTs with Cal/BD aerosol foam in patients with psoriasis. |
| first_indexed | 2024-03-12T00:17:14Z |
| format | Article |
| id | doaj.art-a6d92f2c90934ca3b88685979243ed67 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:17:14Z |
| publishDate | 2021-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-a6d92f2c90934ca3b88685979243ed672023-09-15T14:23:04ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532021-11-0132888389310.1080/09546634.2020.17174171717417Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE)Sascha Gerdes0Manuel Velasco1Jashin J. Wu2Mario Hubo3Karen A. Veverka4Psoriasis Center, Department of Dermatology, University Medical Center Schleswig-Holstein Campus KielHospital Arnau de VilanovaDermatology Research and Education FoundationLEO Pharma GmbHLEO Pharma IncBackground Randomized controlled trials (RCTs) demonstrated the advantages of an aerosol foam formulation of calcipotriol/betamethasone dipropionate (Cal/BD) in patients with psoriasis. In this review, we investigated whether such benefits could also be obtained in real-world clinical practice. Methods PubMed was searched for studies reporting real-world data in patients with psoriasis treated with Cal/BD aerosol foam. Results Three large real-world studies with Cal/BD aerosol foam were identified: a prospective non-interventional study from Germany, a medical chart review from the US, and a retrospective non-interventional study from Spain. Some key findings included the following: high levels of adherence to treatment (82–93%); after 4 weeks, about 50% of patients achieved complete/almost complete responses; at final assessment, 85–95% of patients were extremely satisfied/very satisfied/satisfied with Cal/BD aerosol foam; all healthcare providers were satisfied or somewhat satisfied with the efficacy of Cal/BD foam and they reported similar findings for symptom improvements (itch, pain, erythema/redness, flaking, and plaque thickness). Global ratings by investigators/healthcare providers for symptom control, overall efficacy and the emotional status of patients were also very high (75–100%). Conclusion The results from real-world studies undertaken in diverse healthcare systems reinforce the positive findings reported in RCTs with Cal/BD aerosol foam in patients with psoriasis.http://dx.doi.org/10.1080/09546634.2020.1717417aerosolbetamethasone dipropionatecalcipotriolpsoriasisreal-world evidence |
| spellingShingle | Sascha Gerdes Manuel Velasco Jashin J. Wu Mario Hubo Karen A. Veverka Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE) Journal of Dermatological Treatment aerosol betamethasone dipropionate calcipotriol psoriasis real-world evidence |
| title | Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE) |
| title_full | Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE) |
| title_fullStr | Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE) |
| title_full_unstemmed | Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE) |
| title_short | Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE) |
| title_sort | calcipotriol betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris a review of real world evidence rwe |
| topic | aerosol betamethasone dipropionate calcipotriol psoriasis real-world evidence |
| url | http://dx.doi.org/10.1080/09546634.2020.1717417 |
| work_keys_str_mv | AT saschagerdes calcipotriolbetamethasonedipropionateaerosolfoamforthetreatmentofpsoriasisvulgarisareviewofrealworldevidencerwe AT manuelvelasco calcipotriolbetamethasonedipropionateaerosolfoamforthetreatmentofpsoriasisvulgarisareviewofrealworldevidencerwe AT jashinjwu calcipotriolbetamethasonedipropionateaerosolfoamforthetreatmentofpsoriasisvulgarisareviewofrealworldevidencerwe AT mariohubo calcipotriolbetamethasonedipropionateaerosolfoamforthetreatmentofpsoriasisvulgarisareviewofrealworldevidencerwe AT karenaveverka calcipotriolbetamethasonedipropionateaerosolfoamforthetreatmentofpsoriasisvulgarisareviewofrealworldevidencerwe |